MilliporeSigma Announces Signing of MoU with Gene Therapy Research Institution to Accelerate Viral Vector-based Gene Therapy for Parkinson’s Disease
News Release
- One of first Sf-RVN® Insect Cell Line applications for clinical stage gene therapy production
- Company to support safe and robust production of viral vectors
- Collaboration aims to bring new therapies to market faster
Tokyo, Japan, July 24, 2024 - MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, announced that its Life Science business sector has signed a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors. GTRI will utilize MilliporeSigma’s Sf-RVN® Insect Cell Line platform for the Good Manufacturing Practices (GMP) production of its viral vector-based gene therapy for Parkinson’s Disease.
“In Japan, clinical trials of gene therapy medicines are underway in the hope of developing new treatments to fight and cure diseases,” said Isao Hatano, Head, Process Solutions, Japan, Life Science business of Merck KGaA, Darmstadt, Germany. “With our broad portfolio of products and services, we can better equip and support GTRI in accelerating process development and manufacturing of viral vector-based gene therapy. We believe this collaboration will ultimately help save many patients suffering from serious diseases.”
As part of the MoU, MilliporeSigma will partner with GTRI to build a robust AAV production platform to scale up production. The collaboration will also include the use of MilliporeSigma’s cell line and platform technologies for developing viral vector-based gene therapy. Additionally, MilliporeSigma will provide GTRI with technical support, training and process optimization for process development at the M Lab™ Collaboration Center in Tokyo.
“Since 2014, we have been working to bring our unique gene therapy techniques to refractory diseases where effective therapies have not been established, primarily focusing on Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS),” said Katsuhito Asai, CEO, GTRI. “Our biggest challenge is developing robust and safe manufacturing processes for viral vectors used to introduce DNA into patients, especially on a large scale. Producing viral vectors is much more complex and larger in scale than making typical antibody drugs. Our partnership with MilliporeSigma will optimize this process and help bring therapies to market faster.”
Earlier this year, MilliporeSigma announced a partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance research aimed at slowing progression of Parkinson’s disease.
About Gene Therapy Research Institute Co., Ltd.
Gene Therapy Research Institution Co., Ltd. (GTRI) is a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors. Established in 2014, GTRI aims to realize the innovative research in practice, in the fastest way from basic research to clinical studies with the goal of popularizing gene therapy. https://www.genetherapy-ri.com/en/
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 27,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Latest Press Releases
To continue reading please sign in or create an account.
Don't Have An Account?